ANL 27.50 Decreased By ▼ -0.39 (-1.4%)
ASC 17.01 Decreased By ▼ -0.19 (-1.1%)
ASL 23.90 Decreased By ▼ -0.10 (-0.42%)
AVN 93.69 Increased By ▲ 1.49 (1.62%)
BOP 9.51 Decreased By ▼ -0.16 (-1.65%)
BYCO 9.75 Increased By ▲ 0.05 (0.52%)
DGKC 110.25 Decreased By ▼ -0.75 (-0.68%)
EPCL 47.79 Decreased By ▼ -0.23 (-0.48%)
FCCL 21.27 Decreased By ▼ -0.13 (-0.61%)
FFBL 27.41 Decreased By ▼ -0.46 (-1.65%)
FFL 18.80 Decreased By ▼ -0.20 (-1.05%)
HASCOL 14.56 Decreased By ▼ -0.06 (-0.41%)
HUBC 86.67 Increased By ▲ 2.65 (3.15%)
HUMNL 7.33 Increased By ▲ 0.26 (3.68%)
JSCL 30.94 Increased By ▲ 0.44 (1.44%)
KAPCO 41.05 Increased By ▲ 0.67 (1.66%)
KEL 4.10 Decreased By ▼ -0.01 (-0.24%)
LOTCHEM 16.25 Increased By ▲ 0.35 (2.2%)
MLCF 43.02 Decreased By ▼ -0.09 (-0.21%)
PAEL 39.90 Decreased By ▼ -0.16 (-0.4%)
PIBTL 12.61 Decreased By ▼ -0.08 (-0.63%)
POWER 11.39 Increased By ▲ 0.14 (1.24%)
PPL 94.00 Decreased By ▼ -1.80 (-1.88%)
PRL 23.99 Decreased By ▼ -0.74 (-2.99%)
PTC 9.50 Decreased By ▼ -0.14 (-1.45%)
SILK 1.26 Increased By ▲ 0.04 (3.28%)
SNGP 45.00 Decreased By ▼ -0.83 (-1.81%)
TRG 106.45 Increased By ▲ 0.60 (0.57%)
UNITY 34.18 Increased By ▲ 2.28 (7.15%)
WTL 1.13 Decreased By ▼ -0.02 (-1.74%)
BR100 4,833 Decreased By ▼ -22.35 (-0.46%)
BR30 24,693 Decreased By ▼ -86.65 (-0.35%)
KSE100 45,677 Decreased By ▼ -226.29 (-0.49%)
KSE30 19,026 Decreased By ▼ -127.11 (-0.66%)

Coronavirus vaccine to enter late-stage trial by July end: Researchers

  • Volunteers who have undergone the phase II trial in May have shown positive early results, developing antibodies against the virus
03 Jul 2020

(Karachi) Coronavirus vaccine candidates will enter late-stage clinical studies by the end of the month, with others beginning in August, September and October, the U.S. government’s top infectious diseases expert said on Thursday.

The news comes as Moderna Inc, which is at the forefront of the country’s vaccine development efforts, reiterated earlier in the day that a late-stage trial with 30,000 volunteers would begin this month.

World's first inactivated Covid-19 vaccine produces antibodies: Chinese experts

“We may be able to at least know whether we are dealing with a safe and effective vaccine by the early winter, late winter, (or) beginning of 2021,” Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, said in an interview to JAMA Network.

According to the firm, volunteers who have undergone the phase II trial in May have shown positive early results, developing antibodies against the virus.

AstraZeneca, Moderna ahead in COVID-19 vaccine race: WHO

In June, China National Biotec Group (CNBG) announced that their inactivated COVID-19 vaccine had passed phase one and two clinical trials.

The vaccine showed no "serious adverse reactions" with all volunteers generating antibodies after two doses in 28 days, the company said.